Hikma Pharmaceuticals Management
Management criteria checks 3/4
Hikma Pharmaceuticals' CEO is Riad Mishlawi, appointed in Sep 2023, has a tenure of less than a year. total yearly compensation is $1.55M, comprised of 21.5% salary and 78.5% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth £7.84M. The average tenure of the management team and the board of directors is 3.4 years and 4.8 years respectively.
Key information
Riad Mishlawi
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 21.5% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | 3.4yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28I Ran A Stock Scan For Earnings Growth And Hikma Pharmaceuticals (LON:HIK) Passed With Ease
Feb 22Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 23% Undervaluation?
Feb 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$333k | US$190m |
Compensation vs Market: Riad's total compensation ($USD1.55M) is below average for companies of similar size in the UK market ($USD3.29M).
Compensation vs Earnings: Insufficient data to compare Riad's compensation with company performance.
CEO
Riad Mishlawi (59 yo)
less than a year
Tenure
US$1,552,833
Compensation
Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 16.8yrs | US$3.57m | 0.38% $ 15.5m | |
| CEO & Director | less than a year | US$1.55m | 0.19% $ 7.8m | |
| Executive Vice Chairman & President of MENA | 18.6yrs | US$2.84m | 0.63% $ 25.3m | |
| Chief Financial Officer | 13.3yrs | no data | 0.20% $ 8.2m | |
| Chief Information Officer | no data | no data | no data | |
| Associate Director of Investor Relations | no data | no data | no data | |
| General Counsel | no data | no data | no data | |
| Executive Vice President of Corporate Development and M&A | 10.1yrs | no data | 0.28% $ 11.2m | |
| Chief People Officer | less than a year | no data | no data | |
| Executive Vice President of Strategic Planning & Global Affairs | 6.3yrs | no data | no data | |
| Executive Officer | 6.8yrs | no data | no data | |
| President of Injectables Business | less than a year | no data | no data |
3.4yrs
Average Tenure
59yo
Average Age
Experienced Management: HIK's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 16.8yrs | US$3.57m | 0.38% $ 15.5m | |
| CEO & Director | less than a year | US$1.55m | 0.19% $ 7.8m | |
| Executive Vice Chairman & President of MENA | 18.6yrs | US$2.84m | 0.63% $ 25.3m | |
| Senior Independent Non-Executive Director | 1.4yrs | US$149.27k | no data | |
| Independent Non-Executive Director | 7.5yrs | US$176.38k | 0.0032% $ 129.2k | |
| Independent Non-Executive Director | 8.1yrs | US$159.69k | 0.0016% $ 63.8k | |
| Non-Executive Director | 18.5yrs | US$116.72k | 0.52% $ 21.2m | |
| Independent Non-Executive Director | 3.9yrs | US$149.85k | 0.0020% $ 81.9k | |
| Independent Non-Executive Director | 1.4yrs | US$127.05k | 0.00045% $ 18.2k | |
| Independent Non-Executive Director | 4.8yrs | US$134.68k | 0.00050% $ 20.2k | |
| Chairman of West-ward Pharmaceuticals | no data | no data | no data | |
| Independent Non-Executive Director | 1.5yrs | US$124.98k | no data |
4.8yrs
Average Tenure
65yo
Average Age
Experienced Board: HIK's board of directors are considered experienced (4.8 years average tenure).